Paul A. Calvo, Ph.D. contributed his knowledge of intellectual property law to a recent FirstView Advisory Report. The report discusses current and imminent issues facing the biosimilars market, and how they might shape the evolution of the industry. Dr. Calvo contributed to a discussion concerning the legal tactics now commonly employed by both originator and biosimilar companies.
FirstView aims to provide data, expert opinion, and insight on issues and changes in the pharmaceutical industry. They boast leading market research capabilities and expertise accompanied by more than one million industry contributors.